Letter/Comment
The latest advocacy letters and comments from the American Hospital Association.
This letter expresses AHA’s concern about a forthcoming UnitedHealthcare change in coverage policy for laboratory test services.
This letter provides comment on the proposed rule from the Departments of the Treasury, Labor and Health and Human Services that would allow certain grandfathered health plans to increase patient cost-sharing beyond current limits, without losing their grandfathered status.
While we appreciate the IRS’s effort to provide flexibility to consumers and expand access to affordable health care, we are concerned that, by promoting health care sharing ministries, this rule validates a type of arrangement that can leave consumers vulnerable, as there is no guarantee for…
On behalf of our nearly 5,000 member hospitals, health systems and other health care organizations, our clinical partners – including more than 270,000 affiliated physicians, 2 million nurses and other caregivers – and the 43,000 health care leaders who belong to our professional membership groups…
The American Hospital Association (AHA) urges the Centers for Medicare & Medicaid Services (CMS) to allow periodic interim payment (PIP) hospitals to carry out their accelerated payment repayment at cost settlement, as was initially communicated by the agency. We also request that the agency…
The AHA and other national organizations representing the nation’s hospitals and health systems today urged congressional leaders not to include in the next COVID-19 relief package any surprise medical billing legislation that could further destabilize hospitals’ finances as they work to recover…
The American Hospital Association (AHA) supports the Eliminating the Provider Relief Fund Tax Penalties Act of 2020.
The American Hospital Association (AHA) supports the Eliminating the Provider Relief Fund Tax Penalties Act of 2020.
AHA expresses concern regarding recent action taken by three major drug manufacturers – Eli Lilly and Co., Merck and Sanofi – to limit the distribution of certain 340B drugs to our hospital members.
AHA urges the Centers for Medicare & Medicaid Services to continue its suspension of medical review activities throughout the ongoing COVID-19 public health emergency.